Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 22, 2018
Pharmacy Choice - News - Front Page Healthcare News - April 22, 2018

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/23/18 - "Curcumin Infused Milk Beverage and a Process for the Preparation Thereof" in Patent Application Approval Process (USPTO 20180055787)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor MISRA, Srikumar, filed on August 31, 2016, was made available online on March 8, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or institution. "The plan
3/23/18 - "Stable Ready to Use Cyclophosphamide Liquid Formulations" in Patent Application Approval Process (USPTO 20180055861)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors CHANDRASHEKHAR, Kocherlakota; NAGARAJU, Banda, filed on February 15, 2016, was made available online on March 8, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Leiutis Pharm
3/23/18 - "Vaccine, Therapeutic Composition and Methods for Treating Or Inhibiting Cancer" in Patent Application Approval Process (USPTO 20180055920)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Bishop, Gail, filed on March 11, 2016, was made available online on March 8, 2018, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to University of Iowa Research Foundation. "Currentl
3/23/18 - $280,000 Available in Cooperative Agreements for Modeling Nasal Mucociliary Clearance
The U.S. Department of Health and Human Services' Food and Drug Administration announced that it expects to award up to two cooperative agreements for a three-dimensional approach for modeling nasal mucociliary clearance via computational fluid dynamics. This funding opportunity uses the research project- cooperative agreements mechanism.
3/23/18 - +49% CAGR to Be Achieved by Biosimilars Market According to Market Research, Opportunity Analysis and Global Forecast 2018-2023: Comprehensive Research on Biosimilars Market based on Product (Recombinant Non-glycosylated Proteins, Manufacturing, Appl
Pune, India 03/22/2018 A biosimilar is a biologic medical product which is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products, and can be manufactured when the original product's patent expires. Reference to the innovator pr
3/23/18 - 1st AACC Middle East Conference highlights need for better communication between physicians, lab experts [Emirates News Agency (WAM) (United Arab Emirates)]
ABU DHABI, 23rd March, 2018 Healthcare experts, who gathered in Abu Dhabi to attend the first American Association for Clinical Chemistry, AACC Middle East Conference, said that laboratory automation has increased the productivity and efficiency of clinical laboratories while highlighting the need for improved communication between physicians and
3/23/18 - 2018 "Radio Pharmaceutical Market" Volume and Revenue | By Application - Cardiology, Thyroid, Oncology, Neurology | Leading Player Analysis till 2022
Global Radio pharmaceutical Information, by types by end users- Forecast to 2022. According to a recent study report published by the Market Research Future, the Global Radio Pharmaceutical Market is expected to gain eminence over the forecast period. According to the World Cancer Research Fund International, in 2015, cancer was responsible for 8.8
3/23/18 - 3D Applications in Health Care Market Driven by Technological Advances in 3D Printed Skin: Transparency Market Research Report Added "3D Applications in Health Care Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 20
Albany, NY 03/22/2018 The digital age has certainly evolved and the new generation is now empowered and driven by the latest technology. 3 D technology is one of them and the fastest growing markets in the world. The 3 D imaging market is an outcome of the traditional diagnostic imaging market. 3 D systems in association with doctors, health
3/23/18 - 3D Printed Medical Devices Market Is Expected to Expand at a CAGR of 18.1% During the Forecast Period 2017 to 2027: Future Market Insights has announced the addition of the 3D Printed Medical Devices Market: Global Industry Analysis (2012-2016)
Valley Cottage, NY 03/23/2018 Future Market Insights presents pertinent insights and a revised forecast of the global 3 D printed medical devices market in its published report titled' 3 D Printed Medical Devices Market ": Global Industry Analysis and Opportunity Assessment'. The global 3 D printed medical devices market is expected to expand
3/23/18 - AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer [Arab Finance (Egypt)]
AbbVie, a global research and development-based biopharmaceutical company, today announced that after consulting with the U.S. Food and Drug Administration, it will not seek accelerated approval for Rova-T in third-line relapsed/refractory small cell lung cancer based on magnitude of effect across multiple parameters in this single-arm study.
3/23/18 - AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch [Arab Finance (Egypt)]
Shares cratered on the terse release, free falling 12% and wiping more than $20 billion off its market cap, which started the day at $178 billion. So with an IRC assessment at 16%, AbbVie is well behind the 8 ball, with the FDA chilling talk of an accelerated approval despite the fact that there are no approved options. AbbVie paid $5.8 billion in
3/23/18 - Alere To Pay U.S. $33.2 Million To Settle False Claims Act Allegations Relating To Unreliable Diagnostic Testing Devices
Baltimore, Maryland- Massachusetts- based medical device manufacturer Alere Inc. and its subsidiary Alere San Diego have agreed to pay the United States $33.2 million to resolve allegations that Alere caused hospitals to submit false claims to Medicare and other federal healthcare programs relating to the use of materially unreliable point-of-care.
3/23/18 - AMAG PHARMACEUTICALS INC. FILES (8-K) Disclosing Regulation FD Disclosure
On March 23, 2018, AMAG Pharmaceuticals, Inc. and Sandoz Inc. entered a stipulation of dismissal, in the United States District Court for the District of New Jersey, pursuant to a settlement agreement, that dismisses and resolves the U.S. patent litigation related to the Company's Feraheme, 30 mg/mL, 17 mL single dose vials, for intravenous use.
3/23/18 - AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Regulation FD Disclosure
AMAG PHARMACEUTICALS,INC. (NASDAQ:AMAG) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD. On March 23, 2018, AMAG Pharmaceuticals, Inc. (AMAG or the Company) and Sandoz Inc. entered a stipulation of dismissal, in the United States District Court for the District of New Jersey, to a settlement agreement, that dismisses and re
3/23/18 - Ambulatory Surgical Centres Market Is Projected to Be Valued at US$ 113,046.7 Million by the End of 2027: Future Market Insights has announced the addition of the Ambulatory Surgical Centres Market: Global Industry Analysis and Opportunity Assessm
Valley Cottage, NY 03/23/2018 Future Market Insights delivers key insights and presents a revised forecast of the global ambulatory surgical centres market for a 10 year period from 2017 to 2027 in the report titled "Ambulatory Surgical Centres Market: Global Industry Analysis 2012 2016 and Opportunity Assessment 2017 2027." The revisio
3/23/18 - Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin) For The Treatment Of Three Types Of Cancer
Amgen and Allergan plc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin . ABP 980 has been recommended for approval for the treatment of the same three types of cancer as Herceptin is appr
3/23/18 - Amgen Receives Positive CHMP Opinion Recognizing That Repatha (evolocumab) Prevents Heart Attacks And Strokes
Amgen today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion to include a new indication in the Repatha label for adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels. "We welcome the CHMP's positiv
3/23/18 - Amgen, Allergan: CHMP Adopts Positive Opinion For ABP 980
THOUSAND OAKS- Amgen and Allergan plc. announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin. Amgen and Allergan are collaborating on the development and commercialization of four oncology biosimilars.
3/23/18 - An Application for the Trademark "PERFORM PATIENT EVALUATION RESOURCES FOR OPIOID RISK MANAGEMENT" Has Been Filed by Purdue Pharma
By a News Reporter-Staff News Editor at Drug Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "PERFORM PATIENT EVALUATION RESOURCES FOR OPIOID RISK MANAGEMENT" by Alan L. Koller, representing Purdue Pharma. The owner/registrar information for this application is:
3/23/18 - ARCA biopharma Announces Fiscal Year 2017 Financial Results and Provides Corporate Update
ARCA biopharma, a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2017. Michael Bristow, ARCA s President and Chief Executive Officer. We reported top-line Phase 2 B results for the GENETI
3/23/18 - Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology [Syrian Arab News Agency]
Array BioPharma Inc. today announced that detailed results of its pivotal Phase 3 COLUMBUS trial for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma were published in The Lancet Oncology.
3/23/18 - AstraZeneca hyperkalemia therapy gets EU approval
AstraZeneca plc said the European Commission approved its MAA for Lokelma sodium zirconium cyclosilicate to treat hyperkalemia in adults. In March 2017, AZ received its second complete response letter from FDA for the drug following an FDA inspection of a manufacturing facility. The company expects a decision this half from FDA on a resubmitted NDA
3/23/18 - AstraZeneca provides update on MYSTIC trial timeline
AstraZeneca and MedImmune, its global biologics research and development arm, today announced an updated timeline for the final analysis of the Phase III MYSTIC trial of Imfinzi as monotherapy and in combination with tremelimumab, versus platinum-based standard-of-care chemotherapy in previously-untreated patients with metastatic 1st- line...
3/23/18 - Auris Health Unveils the FDA-Cleared Monarch Platform, Ushering in a New Era of Medical Intervention
Auris Health, Inc., formerly known as Auris Surgical Robotics, Inc., today announced U.S. Food and Drug Administration clearance of the company s Monarch? Platform, ushering in a new era of medical intervention. Founded and led by surgical robotics pioneer Frederic Moll, M.D., Auris has raised more than $500 million in equity capital from lead
3/23/18 - Brain Health Supplements Market 2018-2025: Global Challenges and Opportunities by Types, Regions, Key Players and Applications
The study of "2018 Market Research Report on Global Brain Health Supplements Industry" provides the market size information, In-Depth Analysis along with Competitive Insights and Segmentation. Key Players: Accelerated I...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415